The staphylococcal enterotoxin (SE) family: SEB and siblings

Virulence

Volumn 4, Issue 8, 2013, Pages

  Krakauer, Teresa ^a   Stiles, Bradley G ^b  

^a UNITED STATES ARMY MEDICAL RESEARCH INSTITUTE OF INFECTIOUS DISEASES   (United States)

^b Wilson College   (United States)

Author keywords

Animal model; Cytokine; S. aureus; SEB; Superantigen; Therapeutic; Vaccine

Indexed keywords

CD28 ANTIGEN; DEXAMETHASONE; GAMMA INTERFERON; HLA DR1 ANTIGEN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; IMMUNOPHILIN; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 1; INTERLEUKIN 12; INTERLEUKIN 1BETA; INTERLEUKIN 2; INTERLEUKIN 6; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; MONOCLONAL ANTIBODY; MONOCYTE CHEMOTACTIC PROTEIN 1; MYELOID DIFFERENTIATION FACTOR 88; PENTOXIFYLLINE; PHOSPHODIESTERASE; PHOSPHOLIPASE C GAMMA; PIRFENIDONE; PROTEIN KINASE C; PROTEIN TYROSINE KINASE; RAPAMYCIN; STAPHYLOCOCCUS ENTEROTOXIN; SUPERANTIGEN; T LYMPHOCYTE RECEPTOR; TOXIC SHOCK SYNDROME TOXIN 1; TRANSFORMING GROWTH FACTOR BETA1; TUMOR NECROSIS FACTOR ALPHA; UNINDEXED DRUG; CYTOKINE; ENTEROTOXIN; VACCINE;

ACUTE LUNG INJURY; ANTIBIOTIC RESISTANCE; BACTERIAL VIRULENCE; CELL DIFFERENTIATION; CELL PROLIFERATION; FOOD POISONING; FOOD SAFETY; HAPLORHINI; HUMAN; IMMUNE RESPONSE; INFLAMMATION; NONHUMAN; PHOSPHORYLATION; PROTEIN METHYLATION; RECEPTOR BINDING; REVIEW; SEPTIC SHOCK; SIGNAL TRANSDUCTION; STAPHYLOCOCCUS AUREUS; TELEMETRY; VOMITING; ANIMAL MODEL; IMMUNOLOGY; METABOLISM; MULTIPLE ORGAN FAILURE; S. AUREUS; SEB; SECRETION (PROCESS); SHOCK; THERAPEUTIC;

ANIMAL MODEL; CYTOKINE; S. AUREUS; SEB; SUPERANTIGEN; THERAPEUTIC; VACCINE;

CYTOKINES; ENTEROTOXINS; HUMANS; MULTIPLE ORGAN FAILURE; SHOCK; STAPHYLOCOCCUS AUREUS; SUPERANTIGENS;

EID: 84888344291     PISSN: 21505594     EISSN: 21505608     Source Type: Journal    
DOI: 10.4161/viru.23905     Document Type: Review

References (155)

1. Archer NK, Mazaitis MJ, Costerton JW, Leid JG, Powers ME, Shirtliff ME. Staphylococcus aureus biofilms: properties, regulation, and roles in human disease. Virulence 2011; 2:445-59; PMID:21921685; http://dx.doi.org/10.4161/viru.2.5.17724
2. Uchiyama T, Imanishi K, Miyoshi-Akiyama T, Kata H. Staphylococcal superantigens and the diseases they cause. In: Alouf JE, Popoff MR, eds. The Comprehensive Sourcebook of Bacterial Protein Toxins, 3rd Edition. London, Academic Press, 2006:830-43.
3. Thurlow LR, Joshi GS, Richardson AR. Virulence strategies of the dominant USA300 lineage of community-associated methicillin-resistant Staphylococcus aureus (CA-MRSA). FEMS Immunol Med Microbiol 2012; 65:5-22; PMID:22309135; http://dx.doi.org/10.1111/j.1574-695X.2012.00937.x
4. Graham PL 3rd, Lin SX, Larson EL. A U.S. populationbased survey of Staphylococcus aureus colonization. Ann Intern Med 2006; 144:318-25; PMID:16520472.
5. Fraser JD, Proft T. The bacterial superantigen and superantigen-like proteins. Immunol Rev 2008; 225:226-43; PMID:18837785; http://dx.doi.org/10.1111/j.1600-065X.2008.00681.x
6. Tang YW, Stratton CW. Staphylococcus aureus: An old pathogen with new weapons. Clin Lab Med 2010; 30:179-208; PMID:20513547; http://dx.doi.org/10.1016/j.cll.2010.01.005
7. Gould IM, David MZ, Esposito S, Garau J, Lina G, Mazzei T, et al. New insights into meticillin-resistant Staphylococcus aureus (MRSA) pathogenesis, treatment and resistance. Int J Antimicrob Agents 2012; 39:96-104; PMID:22196394; http://dx.doi.org/10.1016/j.ijantimicag.2011.09.028
8. van Hal SJ, Lodise TP, Paterson DL. The clinical significance of vancomycin minimum inhibitory concentration in Staphylococcus aureus infections: a systematic review and meta-analysis. Clin Infect Dis 2012; 54:755-71; PMID:22302374; http://dx.doi.org/10.1093/cid/cir935
9. David MZ, Medvedev S, Hohmann SF, Ewigman B, Daum RS. Increasing burden of methicillin-resistant Staphylococcus aureus hospitalizations at US academic medical centers, 2003-2008. Infect Control Hosp Epidemiol 2012; 33:782-9; PMID:22759545; http://dx.doi.org/10.1086/666640
10. Ulrich RG, Wilhelmsen CL, Krakauer TD. Staphylococcal enterotoxin B and related toxins. In: Dembek Z, Textbook of Military Medicine: Medical Aspects of Biological Warfare, US Department of Army. Washington DC, Borden Institute, 2007: 311-22.
11. Madsen JM. Toxins as weapons of mass destruction. A comparison and contrast with biological-warfare and chemical-warfare agents. Clin Lab Med 2001; 21:593-605; PMID:11577702.
12. Le Loir Y, Baron F, Gautier M. Staphylococcus aureus and food poisoning. Genet Mol Res 2003; 2:63-76; PMID:12917803.
13. McGann VG, Rollins JB, Mason DW. Evaluation of resistance to staphylococcal enterotoxin B: naturally acquired antibodies of man and monkey. J Infect Dis 1971; 124:206-13; PMID:5001454; http://dx.doi.org/10.1093/infdis/124.2.206
14. Bergdoll MS. Monkey feeding test for staphylococcal enterotoxin. Methods Enzymol 1988; 165:324-33; PMID:3231111; http://dx.doi.org/10.1016/S0076-6879(88)65048-8
15. Schelin J, Wallin-Carlquist N, Cohn MT, Lindqvist R, Barker GC, Rådström P. The formation of Staphylococcus aureus enterotoxin in food environments and advances in risk assessment. Virulence 2011; 2:580-92; PMID:22030860; http://dx.doi.org/10.4161/viru.2.6.18122
16. Chowdhary VR, Tilahun AY, Clark CR, Grande JP, Rajagopalan G. Chronic exposure to staphylococcal superantigen elicits a systemic inflammatory disease mimicking lupus. J Immunol 2012; 189:2054-62; PMID:22798666; http://dx.doi.org/10.4049/jimmunol.1201097
17. Jett M, Brinkley W, Neill R, Gemski P, Hunt R. Staphylococcus aureus enterotoxin B challenge of monkeys: correlation of plasma levels of arachidonic acid cascade products with occurrence of illness. Infect Immun 1990; 58:3494-9; PMID:2172165.
18. Scheuber PH, Denzlinger C, Wilker D, Beck G, Keppler D, Hammer DK. Staphylococcal enterotoxin B as a nonimmunological mast cell stimulus in primates: the role of endogenous cysteinyl leukotrienes. Int Arch Allergy Appl Immunol 1987; 82:289-91; PMID:3032802; http://dx.doi.org/10.1159/000234209
19. Parsonnet J, Hansmann MA, Seymour JL, Delaney ML, Dubois AM, Modern PA, et al. Persistence survey of toxic shock syndrome toxin-1 producing Staphylococcus aureus and serum antibodies to this superantigen in five groups of menstruating women. BMC Infect Dis 2010; 10:249; PMID:20731864; http://dx.doi.org/10.1186/1471-2334-10-249
20. Mahlknecht U, Herter M, Hoffmann MK, Niethammer D, Dannecker GE. The toxic shock syndrome toxin-1 induces anergy in human T cells in vivo. Hum Immunol 1996; 45:42-5; PMID:8655359; http://dx.doi.org/10.1016/0198-8859(95)00145-X
21. Hofer MF, Newell K, Duke RC, Schlievert PM, Freed JH, Leung DY. Differential effects of staphylococcal toxic shock syndrome toxin-1 on B cell apoptosis. Proc Natl Acad Sci U S A 1996; 93:5425-30; PMID:8643591; http://dx.doi.org/10.1073/pnas.93.11.5425
22. Stiles BG, Krakauer T, Bonventre PF. Biological activity of toxic shock syndrome toxin 1 and a site-directed mutant, H135A, in a lipopolysaccharide-potentiated mouse lethality model. Infect Immun 1995; 63:1229-34; PMID:7890377.
23. Stiles BG, Garza AR, Ulrich RG, Boles JW. Mucosal vaccination with recombinantly attenuated staphylococcal enterotoxin B and protection in a murine model. Infect Immun 2001; 69:2031-6; PMID:11254555; http://dx.doi.org/10.1128/IAI.69.4.2031-2036.2001
24. Nilsson IM, Verdrengh M, Ulrich RG, Bavari S, Tarkowski A. Protection against Staphylococcus aureus sepsis by vaccination with recombinant staphylococcal enterotoxin A devoid of superantigenicity. J Infect Dis 1999; 180:1370-3; PMID:10479175; http://dx.doi.org/10.1086/315023
25. Bavari S, Dyas B, Ulrich RG. Superantigen vaccines: a comparative study of genetically attenuated receptorbinding mutants of staphylococcal enterotoxin A. J Infect Dis 1996; 174:338-45; PMID:8699064; http://dx.doi.org/10.1093/infdis/174.2.338
26. Ulrich RG, Olson MA, Bavari S. Development of engineered vaccines effective against structurally related bacterial superantigens. Vaccine 1998; 16:1857-64; PMID:9795392; http://dx.doi.org/10.1016/S0264-410X(98)00176-5
27. Hu DL, Omoe K, Sasaki S, Sashinami H, Sakuraba H, Yokomizo Y, et al. Vaccination with nontoxic mutant toxic shock syndrome toxin 1 protects against Staphylococcus aureus infection. J Infect Dis 2003; 188:743-52; PMID:12934191; http://dx.doi.org/10.1086/377308
28. Schlievert PM. Use of intravenous immunoglobulin in the treatment of staphylococcal and streptococcal toxic shock syndromes and related illnesses. J Allergy Clin Immunol 2001; 108(Suppl):S107-10; PMID:11586276; http://dx.doi.org/10.1067/mai.2001.117820
29. Toussaint S, Gerlach H. Immunoglobulins in adult sepsis and septic shock. Curr Infect Dis Rep 2012; 14:522-9; PMID:22886554; http://dx.doi.org/10.1007/s11908-012-0287-z
30. Tilahun ME, Rajagopolan G, Shah-Mahoney N, Lawlor RG, Tilahun AY, Xie C, et al. Potent neutralization of staphylococcal enterotoxin B by synergistic action of chimeric antibodies. Infect Immun 2010; 78:2801-11; PMID:20308304; http://dx.doi.org/10.1128/IAI.01121-09
31. Nowakowski A, Wang C, Powers DB, Amersdorfer P, Smith TJ, Montgomery VA, et al. Potent neutralization of botulinum neurotoxin by recombinant oligoclonal antibody. Proc Natl Acad Sci U S A 2002; 99:11346-50; PMID:12177434; http://dx.doi.org/10.1073/pnas.172229899
32. Choi YW, Kotzin B, Herron L, Callahan J, Marrack P, Kappler J. Interaction of Staphylococcus aureus toxin "superantigens" with human T cells. Proc Natl Acad Sci U S A 1989; 86:8941-5; PMID:2479030; http://dx.doi.org/10.1073/pnas.86.22.8941
33. rd Edition. London, Academic Press, 2006:821-9.
34. Smith-Garvin JE, Koretzky GA, Jordan MS. T cell activation. Annu Rev Immunol 2009; 27:591-619; PMID:19132916; http://dx.doi.org/10.1146/annurev.immunol.021908.132706
35. Lina G, Bohach GA, Nair SP, Hiramatsu K, Jouvin Marche E, Mariuzza R; International Nomenclature Committee for Staphylococcal Superantigens. Standard nomenclature for the superantigens expressed by Staphylococcus. J Infect Dis 2004; 189:2334-6; PMID:15181583; http://dx.doi.org/10.1086/420852
36. Singh BR, Fu FN, Ledoux DN. Crystal and solution structures of superantigenic staphylococcal enterotoxins compared. Nat Struct Biol 1994; 1:358-60; PMID:7664046; http://dx.doi.org/10.1038/nsb0694-358
37. Papageorgiou AC, Tranter HS, Acharya KR. Crystal structure of microbial superantigen staphylococcal enterotoxin B at 1.5 A resolution: implications for superantigen recognition by MHC class II molecules and T-cell receptors. J Mol Biol 1998; 277:61-79; PMID:9514739; http://dx.doi.org/10.1006/jmbi.1997.1577
38. Garcia C, Briggs C, Zhang L, Guan L, Gabriel JL, Rogers TJ. Molecular characterization of the putative T-cell receptor cavity of the superantigen staphylococcal enterotoxin B. Immunology 1998; 94:160-6; PMID:9741336; http://dx.doi.org/10.1046/j.1365-2567.1998.00493.x
39. Kappler JW, Herman A, Clements J, Marrack P. Mutations defining functional regions of the superantigen staphylococcal enterotoxin B. J Exp Med 1992; 175:387-96; PMID:1370682; http://dx.doi.org/10.1084/jem.175.2.387
40. Kum WW, Chow AW. Inhibition of staphylococcal enterotoxin A-induced superantigenic and lethal activities by a monoclonal antibody to toxic shock syndrome toxin-1. J Infect Dis 2001; 183:1739-48; PMID:11372026; http://dx.doi.org/10.1086/320732
41. Bavari S, Ulrich RG, LeClaire RD. Cross-reactive antibodies prevent the lethal effects of Staphylococcus aureus superantigens. J Infect Dis 1999; 180:1365-9; PMID:10479174; http://dx.doi.org/10.1086/314977
42. Larkin EA, Stiles BG, Ulrich RG. Inhibition of toxic shock by human monoclonal antibodies against staphylococcal enterotoxin B. PLoS One 2010; 5:e13253; PMID:20949003; http://dx.doi.org/10.1371/journal.pone.0013253
43. Jardetzky TS, Brown JH, Gorga JC, Stern LJ, Urban RG, Chi YI, et al. Three-dimensional structure of a human class II histocompatibility molecule complexed with superantigen. Nature 1994; 368:711-8; PMID:8152483; http://dx.doi.org/10.1038/368711a0
44. Redpath S, Alam SM, Lin CM, O'Rourke AM, Gascoigne NR. Cutting edge: trimolecular interaction of TCR with MHC class II and bacterial superantigen shows a similar affinity to MHC:peptide ligands. J Immunol 1999; 163:6-10; PMID:10384091.
45. Yagi JJ, Rath S, Janeway CA Jr. Control of T cell responses to staphylococcal enterotoxins by stimulator cell MHC class II polymorphism. J Immunol 1991; 147:1398-405; PMID:1907996.
46. Kim J, Urban RG, Strominger JL, Wiley DC. Toxic shock syndrome toxin-1 complexed with a class II major histocompatibility molecule HLA-DR1. Science 1994; 266:1870-4; PMID:7997880; http://dx.doi.org/10.1126/science.7997880
47. Seo KS, Park JY, Terman DS, Bohach GA. A quantitative real time PCR method to analyze T cell receptor Vbeta subgroup expansion by staphylococcal superantigens. J Transl Med 2010; 8:2; PMID:20070903; http://dx.doi.org/10.1186/1479-5876-8-2
48. Newton DW, Dohlsten M, Olsson C, Segrén S, Lundin KE, Lando PA, et al. Mutations in the MHC class II binding domains of staphylococcal enterotoxin A differentially affect T cell receptor Vbeta specificity. J Immunol 1996; 157:3988-94; PMID:8892632.
49. Arad G, Levy R, Nasie I, Hillman D, Rotfogel Z, Barash U, et al. Binding of superantigen toxins into the CD28 homodimer interface is essential for induction of cytokine genes that mediate lethal shock. PLoS Biol 2011; 9:e1001149; PMID:21931534; http://dx.doi.org/10.1371/journal.pbio.1001149
50. Krakauer T. Small nonpeptide inhibitors of staphylococcal superantigen-induced cytokine production and toxic shock. In: Kotb M, Fraser JD, eds. Superantigens, Molecular Basis for Their Role in Human Diseases. ASM Press, 2007.229-44.
51. Cemerski S, Shaw A. Immune synapses in T-cell activation. Curr Opin Immunol 2006; 18:298-304; PMID:16603343; http://dx.doi.org/10.1016/j.coi.2006.03.011
52. Krakauer T. Costimulatory receptors for the superantigen staphylococcal enterotoxin B on human vascular endothelial cells and T cells. J Leukoc Biol 1994; 56:458-63; PMID:7930941.
53. Kissner TL, Ruthel G, Alam S, Mann E, Ajami D, Rebek M, et al. Therapeutic inhibition of proinflammatory signaling and toxicity to staphylococcal enterotoxin B by a synthetic dimeric BB-loop mimetic of MyD88. PLoS One 2012; 7:e40773; PMID:22848400; http://dx.doi.org/10.1371/journal. pone.0040773
54. Krakauer T. Induction of CC chemokines in human peripheral blood mononuclear cells by staphylococcal exotoxins and its prevention by pentoxifylline. J Leukoc Biol 1999; 66:158-64; PMID:10411004.
55. Krakauer T. Differential inhibitory effects of interleukin-10, interleukin-4, and dexamethasone on staphylococcal enterotoxin-induced cytokine production and T cell activation. J Leukoc Biol 1995; 57:450-4; PMID:7884317.
56. Krakauer T, Stiles BG. Pentoxifylline inhibits superantigen-induced toxic shock and cytokine release. Clin Diagn Lab Immunol 1999; 6:594-8; PMID:10391869.
57. Hale ML, Margolin SB, Krakauer T, Roy CJ, Stiles BG. Pirfenidone blocks the in vitro and in vivo effects of staphylococcal enterotoxin B. Infect Immun 2002; 70:2989-94; PMID:12010989; http://dx.doi.org/10.1128/IAI.70.6.2989-2994.2002
58. Hermann C, von Aulock S, Graf K, Hartung T. A model of human whole blood lymphokine release for in vitro and ex vivo use. J Immunol Methods 2003; 275:69-79; PMID:12667671; http://dx.doi.org/10.1016/S0022-1759(03)00003-6
59. Carlsson R, Fischer H, Sjögren HO. Binding of staphylococcal enterotoxin A to accessory cells is a requirement for its ability to activate human T cells. J Immunol 1988; 140:2484-8; PMID:3258609.
60. Lagoo AS, Lagoo-Deenadayalan S, Lorenz HM, Byrne J, Barber WH, Hardy KJ. IL-2, IL-4, and IFN-gamma gene expression versus secretion in superantigen-activated T cells. Distinct requirement for costimulatory signals through adhesion molecules. J Immunol 1994; 152:1641-52; PMID:8120374.
61. Huvenne W, Callebaut I, Reekmans K, Hens G, Bobic S, Jorissen M, et al. Staphylococcus aureus enterotoxin B augments granulocyte migration and survival via airway epithelial cell activation. Allergy 2010; 65:1013-20; PMID:20132156; http://dx.doi.org/10.1111/j.1398-9995.2009.02313.x
62. Stohl W, Elliott JE, Linsley PS. Human T celldependent B cell differentiation induced by staphylococcal superantigens. J Immunol 1994; 153:117-27; PMID:7515921.
63. Hamad AR, Marrack P, Kappler JW. Transcytosis of staphylococcal superantigen toxins. J Exp Med 1997; 185:1447-54; PMID:9126925; http://dx.doi.org/10.1084/jem.185.8.1447
64. Shupp JW, Jett M, Pontzer CH. Identification of a transcytosis epitope on staphylococcal enterotoxins. Infect Immun 2002; 70:2178-86; PMID:11895985; http://dx.doi.org/10.1128/IAI.70.4.2178-2186.2002
65. Spiekermann GM, Nagler-Anderson C. Oral administration of the bacterial superantigen staphylococcal enterotoxin B induces activation and cytokine production by T cells in murine gut-associated lymphoid tissue. J Immunol 1998; 161:5825-31; PMID:9834060.
66. Hodoval LF, Morris EL, Crawley GJ, Beisel WR. Pathogenesis of lethal shock after intravenous staphylococcal enterotoxin B in monkeys. Appl Microbiol 1968; 16:187-92; PMID:4967067.
67. Raj HD, Bergdoll MS. Effect of enterotoxin B on human volunteers. J Bacteriol 1969; 98:833-4; PMID:4977485.
68. Tilahun AY, Holz M, Wu TT, David CS, Rajagopalan G. Interferon gamma-dependent intestinal pathology contributes to the lethality in bacterial superantigen-induced toxic shock syndrome. PLoS One 2011; 6:e16764; PMID:21304813; http://dx.doi.org/10.1371/journal.pone.0016764
69. Neumann B, Engelhardt B, Wagner H, Holzmann B. Induction of acute inflammatory lung injury by staphylococcal enterotoxin B. J Immunol 1997; 158:1862-71; PMID:9029127.
70. Lu J, Wang A, Ansari S, Hershberg RM, McKay DM. Colonic bacterial superantigens evoke an inflammatory response and exaggerate disease in mice recovering from colitis. Gastroenterology 2003; 125:1785-95; PMID:14724831; http://dx.doi.org/10.1053/j.gastro.2003.09.020
71. Buxser S, Bonventre PF. Staphylococcal enterotoxins fail to disrupt membrane integrity or synthetic functions of Henle 407 intestinal cells. Infect Immun 1981; 31:929-34; PMID:7228407.
72. Lu J, Philpott DJ, Saunders PR, Perdue MH, Yang PC, McKay DM. Epithelial ion transport and barrier abnormalities evoked by superantigen-activated immune cells are inhibited by interleukin-10 but not interleukin-4. J Pharmacol Exp Ther 1998; 287:128-36; PMID:9765331.
73. McKay DM. Bacterial superantigens: provocateurs of gut dysfunction and inflammation? Trends Immunol 2001; 22:497-501; PMID:11525940; http://dx.doi.org/10.1016/S1471-4906(01)02000-2
74. Krakauer T. Stimulant-dependent modulation of cytokines and chemokines by airway epithelial cells: cross talk between pulmonary epithelial and peripheral blood mononuclear cells. Clin Diagn Lab Immunol 2002; 9:126-31; PMID:11777841.
75. Hanna-Wakim R, Yasukawa LL, Sung P, Fang M, Sullivan B, Rinki M, et al. Age-related increase in the frequency of CD4(+) T cells that produce interferongamma in response to staphylococcal enterotoxin B during childhood. J Infect Dis 2009; 200:1921-7; PMID:19909079; http://dx.doi.org/10.1086/648375
76. Hoffman M, Tremaine M, Mansfield J, Betley M. Biochemical and mutational analysis of the histidine residues of staphylococcal enterotoxin A. Infect Immun 1996; 64:885-90; PMID:8641796.
77. Alber G, Hammer DK, Fleischer B. Relationship between enterotoxic and T lymphocyte-stimulating activity of staphylococcal enterotoxin B. J Immunol 1990; 144:4501-6; PMID:2161873.
78. Krakauer T, Buckley MJ, Fisher D. Proinflammatory mediators of toxic shock and their correlation to lethality. Mediators Inflamm 2010; 2010:517594; PMID:20634937; http://dx.doi.org/10.1155/2010/517594
79. Krakauer T, Buckley MJ, Huzella LM, Alves DA. Critical timing, location and duration of glucocorticoid administration rescue mice from superantigen-induced shock and attenuate lung injury. Int Immunopharmacol 2009; 9:1168-74; PMID:19539058; http://dx.doi.org/10.1016/j.intimp.2009.06.004
80. Krakauer T, Buckley M, Fisher D. Murine models of staphylococcal enterotoxin B-induced toxic shock. Mil Med 2010; 175:917-22; PMID:21121506.
81. Stiles BG, Bavari S, Krakauer T, Ulrich RG. Toxicity of staphylococcal enterotoxins potentiated by lipopolysaccharide: major histocompatibility complex class II molecule dependency and cytokine release. Infect Immun 1993; 61:5333-8; PMID:8225606.
82. Chen JY, Qiao Y, Komisar JL, Baze WB, Hsu IC, Tseng J. Increased susceptibility to staphylococcal enterotoxin B intoxication in mice primed with actinomycin D. Infect Immun 1994; 62:4626-31; PMID:7927730.
83. Sarawar SR, Blackman MA, Doherty PC. Superantigen shock in mice with an inapparent viral infection. J Infect Dis 1994; 170:1189-94; PMID:7963712; http://dx.doi.org/10.1093/infdis/170.5.1189
84. Dinges MM, Schlievert PM. Comparative analysis of lipopolysaccharide-induced tumor necrosis factor alpha activity in serum and lethality in mice and rabbits pretreated with the staphylococcal superantigen toxic shock syndrome toxin 1. Infect Immun 2001; 69:7169-72; PMID:11598096; http://dx.doi.org/10.1128/IAI.69.11.7169-7172.2001
85. Moon IJ, Hong SL, Kim DY, Lee CH, Rhee CS, Min YG. Blocking interleukin-17 attenuates enhanced inflammation by staphylococcal enterotoxin B in murine allergic rhinitis model. Acta Otolaryngol 2012; 132(Suppl 1):S6-12; PMID:22582785; http://dx.doi.org/10.3109/00016489.2012.661074
86. Fernandez S, Cisney ED, Hall SI, Ulrich RG. Nasal immunity to staphylococcal toxic shock is controlled by the nasopharynx-associated lymphoid tissue. Clin Vaccine Immunol 2011; 18:667-75; PMID:21325486; http://dx.doi.org/10.1128/CVI.00477-10
87. Miethke T, Wahl C, Heeg K, Echtenacher B, Krammer PH, Wagner H. T cell-mediated lethal shock triggered in mice by the superantigen staphylococcal enterotoxin B: critical role of tumor necrosis factor. J Exp Med 1992; 175:91-8; PMID:1730929; http://dx.doi.org/10.1084/jem.175.1.91
88. Paiva CN, Pyrrho AS, Lannes-Vieira J, Vacchio M, Soares MB, Gattass CR. Trypanosoma cruzi sensitizes mice to fulminant SEB-induced shock: overrelease of inflammatory cytokines and independence of Chagas' disease or TCR Vbeta-usage. Shock 2003; 19:163-8; PMID:12578126; http://dx.doi.org/10.1097/00024382-200302000-00013
89. +CD25 T cells with anergic and suppressive genetic signatures. Clin Exp Immunol 2009; 155:348-56; PMID:19040605; http://dx.doi.org/10.1111/j.1365-2249.2008.03827.x
90. Eroukhmanoff L, Oderup C, Ivars F. T-cell tolerance induced by repeated antigen stimulation: selective loss of Foxp3 conventional CD4 T cells and induction of CD4 T-cell anergy. Eur J Immunol 2009; 39:1078-87; PMID:19283777; http://dx.doi.org/10.1002/eji.200838653
91. Collins LV, Eriksson K, Ulrich RG, Tarkowski A. Mucosal tolerance to a bacterial superantigen indicates a novel pathway to prevent toxic shock. Infect Immun 2002; 70:2282-7; PMID:11953361; http://dx.doi.org/10.1128/IAI.70.5.2282-2287.2002
92. Stiles BG, Campbell YG, Castle RM, Grove SA. Correlation of temperature and toxicity in murine studies of staphylococcal enterotoxins and toxic shock syndrome toxin 1. Infect Immun 1999; 67:1521-5; PMID:10024605.
93. Beno DW, Uhing MR, Jiyamapa-Serna VA, Goto M, Chen Y, Vasan A, et al. Differential induction of hepatic dysfunction after intraportal and intravenous challenge with endotoxin and Staphylococcal enterotoxin B. Shock 2003; 19:352-7; PMID:12688547; http://dx.doi.org/10.1097/00024382-200304000-00010
94. Schlievert PM. Enhancement of host susceptibility to lethal endotoxin shock by staphylococcal pyrogenic exotoxin type C. Infect Immun 1982; 36:123-8; PMID:7042568.
95. Chow AW, Bartlett KH, Percival-Smith R, Morrison BJ. Vaginal colonization with Staphylococcus aureus, positive for toxic-shock marker protein, and Escherichia coli in healthy women. J Infect Dis 1984; 150:80-4; PMID:6379062; http://dx.doi.org/10.1093/infdis/150.1.80
96. Florquin S, Amraoui Z, Abramowicz D, Goldman M. Systemic release and protective role of IL-10 in staphylococcal enterotoxin B-induced shock in mice. J Immunol 1994; 153:2618-23; PMID:7915740.
97. Manjunath N, Correa M, Ardman M, Ardman B. Negative regulation of T-cell adhesion and activation by CD43. Nature 1995; 377:535-8; PMID:7566153; http://dx.doi.org/10.1038/377535a0
98. Yeung RS, Penninger JM, Kündig T, Khoo W, Ohashi PS, Kroemer G, et al. Human CD4 and human major histocompatibility complex class II (DQ6) transgenic mice: supersensitivity to superantigeninduced septic shock. Eur J Immunol 1996; 26:1074-82; PMID:8647170; http://dx.doi.org/10.1002/eji.1830260518
99. Silverstein R. D-galactosamine lethality model: scope and limitations. J Endotoxin Res 2004; 10:147-62; PMID:15198850.
100. DaSilva L, Welcher BC, Ulrich RG, Aman MJ, David CS, Bavari S. Humanlike immune response of human leukocyte antigen-DR3 transgenic mice to staphylococcal enterotoxins: a novel model for superantigen vaccines. J Infect Dis 2002; 185:1754-60; PMID:12085321; http://dx.doi.org/10.1086/340828
101. Roy CJ, Warfield KL, Welcher BC, Gonzales RF, Larsen T, Hanson J, et al. Human leukocyte antigen DQ8 transgenic mice: a model to examine the toxicity of aerosolized staphylococcal enterotoxin B. Infect Immun 2005; 73:2452-60; PMID:15784591; http://dx.doi.org/10.1128/IAI.73.4.2452-2460.2005
102. Zhao YX, Abdelnour A, Kalland T, Tarkowski A. Overexpression of the T-cell receptor V beta 3 in transgenic mice increases mortality during infection by enterotoxin A-producing Staphylococcus aureus. Infect Immun 1995; 63:4463-9; PMID:7591086.
103. Vlach KD, Boles JW, Stiles BG. Telemetric evaluation of body temperature and physical activity as predictors of mortality in a murine model of staphylococcal enterotoxic shock. Comp Med 2000; 50:160-6; PMID:10857007.
104. Boles JW, Pitt ML, LeClaire RD, Gibbs PH, Ulrich RG, Bavari S. Correlation of body temperature with protection against staphylococcal enterotoxin B exposure and use in determining vaccine dose-schedule. Vaccine 2003; 21:2791-6; PMID:12798619; http://dx.doi.org/10.1016/S0264-410X(03)00222-6
105. Huzella LM, Buckley MJ, Alves DA, Stiles BG, Krakauer T. Central roles for IL-2 and MCP-1 following intranasal exposure to SEB: a new mouse model. Res Vet Sci 2009; 86:241-7; PMID:18793785; http://dx.doi.org/10.1016/j.rvsc.2008.07.020
106. Rajagopalan G, Sen MM, Singh M, Murali NS, Nath KA, Iijima K, et al. Intranasal exposure to staphylococcal enterotoxin B elicits an acute systemic inflammatory response. Shock 2006; 25:647-56; PMID:16721274; http://dx.doi.org/10.1097/01.shk.0000209565.92445.7d
107. Huang WT, Lin MT, Won SJ. Staphylococcal enterotoxin A-induced fever is associated with increased circulating levels of cytokines in rabbits. Infect Immun 1997; 65:2656-62; PMID:9199433.
108. Mattix ME, Hunt RE, Wilhelmsen CL, Johnson AJ, Baze WB. Aerosolized staphylococcal enterotoxin B-induced pulmonary lesions in rhesus monkeys (Macaca mulatta). Toxicol Pathol 1995; 23:262-8; PMID:7659951; http://dx.doi.org/10.1177/019262339502300304
109. Boles JW, Pitt ML, LeClaire RD, Gibbs PH, Torres E, Dyas B, et al. Generation of protective immunity by inactivated recombinant staphylococcal enterotoxin B vaccine in nonhuman primates and identification of correlates of immunity. Clin Immunol 2003; 108:51-9; PMID:12865071; http://dx.doi.org/10.1016/S1521-6616(03)00066-4
110. + T cells have defective expression and function of the activating protein-1 transcription factor. J Immunol 1998; 161:5930-6; PMID:9834073.
111. Florquin S, Amraoui Z, Goldman M. T cells made deficient in interleukin-2 production by exposure to staphylococcal enterotoxin B in vivo are primed for interferon-gamma and interleukin-10 secretion. Eur J Immunol 1995; 25:1148-53; PMID:7774618; http://dx.doi.org/10.1002/eji.1830250503
112. Parsonnet J, Gillis ZA, Richter AG, Pier GB. A rabbit model of toxic shock syndrome that uses a constant, subcutaneous infusion of toxic shock syndrome toxin 1. Infect Immun 1987; 55:1070-6; PMID:3570455.
113. de Azavedo JCS, Arbuthnott JP. Toxicity of staphylococcal toxic shock syndrome toxin 1 in rabbits. Infect Immun 1984; 46:314-7; PMID:6500691.
114. Pettit GW, Elwell MR, Jahrling PB. Possible endotoxemia in rabbits after intravenous injection of Staphylococcus aureus enterotoxin B. J Infect Dis 1977; 135:646-8; PMID:856919; http://dx.doi.org/10.1093/infdis/135.4.646
115. Strandberg KL, Rotschafer JH, Vetter SM, Buonpane RA, Kranz DM, Schlievert PM. Staphylococcal superantigens cause lethal pulmonary disease in rabbits. J Infect Dis 2010; 202:1690-7; PMID:20979456; http://dx.doi.org/10.1086/657156
116. Van Miert AS, Van Duin CT, Schotman AJ. Comparative observations of fever and associated clinical hematological and blood biochemical changes after intravenous administration of staphylococcal enterotoxins B and F (toxic shock syndrome toxin-1) in goats. Infect Immun 1984; 46:354-60; PMID:6500695.
117. Hui J, Cao Y, Xiao F, Zhang J, Li H, Hu F. Staphylococcus aureus enterotoxin C2 mutants: biological activity assay in vitro. J Ind Microbiol Biotechnol 2008; 35:975-80; PMID:18506495; http://dx.doi.org/10.1007/s10295-008-0372-3
118. Hu DL, Omoe K, Sashinami H, Shinagawa K, Nakane A. Immunization with a nontoxic mutant of staphylococcal enterotoxin A, SEAD227A, protects against enterotoxin-induced emesis in house musk shrews. J Infect Dis 2009; 199:302-10; PMID:19133806; http://dx.doi.org/10.1086/596065
119. Maina EK, Hu DL, Tsuji T, Omoe K, Nakane A. Staphylococcal enterotoxin A has potent superantigenic and emetic activities but not diarrheagenic activity. Int J Med Microbiol 2012; 302:88-95; PMID:22424598; http://dx.doi.org/10.1016/j.ijmm.2012.01.003
120. Arad G, Levy R, Hillman D, Kaempfer R. Superantigen antagonist protects against lethal shock and defines a new domain for T-cell activation. Nat Med 2000; 6:414-21; PMID:10742148; http://dx.doi.org/10.1038/74672
121. Visvanathan K, Charles A, Bannan J, Pugach P, Kashfi K, Zabriskie JB. Inhibition of bacterial superantigens by peptides and antibodies. Infect Immun 2001; 69:875-84; PMID:11159981; http://dx.doi.org/10.1128/IAI.69.2.875-884.2001
122. Wang S, Li Y, Xiong H, Cao J. A broad-spectrum inhibitory peptide against staphylococcal enterotoxin superantigen SEA, SEB and SEC. Immunol Lett 2008; 121:167-72; PMID:19028523; http://dx.doi.org/10.1016/j.imlet.2008.10.007
123. Hong-Geller E, Möllhoff M, Shiflett PR, Gupta G. Design of chimeric receptor mimics with different TcRVbeta isoforms. Type-specific inhibition of superantigen pathogenesis. J Biol Chem 2004; 279:5676-84; PMID:14604991; http://dx.doi.org/10.1074/jbc.M309388200
124. Wang N, Mattis DM, Sundberg EJ, Schlievert PM, Kranz DM. A single, engineered protein therapeutic agent neutralizes exotoxins from both Staphylococcus aureus and Streptococcus pyogenes. Clin Vaccine Immunol 2010; 17:1781-9; PMID:20861327; http://dx.doi.org/10.1128/CVI.00277-10
125. DeGrasse JA. A single-stranded DNA aptamer that selectively binds to Staphylococcus aureus enterotoxin B. PLoS One 2012; 7:e33410; PMID:22438927; http://dx.doi.org/10.1371/journal.pone.0033410
126. DiDonato JA, Mercurio F, Karin MNF. NF-κB and the link between inflammation and cancer. Immunol Rev 2012; 246:379-400; PMID:22435567; http://dx.doi.org/10.1111/j.1600-065X.2012.01099.x
127. Vallabhapurapu S, Karin M. Regulation and function of NF-kappaB transcription factors in the immune system. Annu Rev Immunol 2009; 27:693-733; PMID:19302050; http://dx.doi.org/10.1146/annurev.immunol.021908.132641
128. Liu D, Zienkiewicz J, DiGiandomenico A, Hawiger J. Suppression of acute lung inflammation by intracellular peptide delivery of a nuclear import inhibitor. Mol Ther 2009; 17:796-802; PMID:19259070; http://dx.doi.org/10.1038/mt.2009.18
129. Tilahun AY, Theuer JE, Patel R, David CS, Rajagopalan G. Detrimental effect of the proteasome inhibitor, bortezomib in bacterial superantigen and lipopolysaccharide-induced systemic inflammation. Mol Ther 2010; 18:1143-54; PMID:20372109; http://dx.doi.org/10.1038/mt.2010.53
130. Krakauer T, Buckley M. Dexamethasone attenuates staphylococcal enterotoxin B-induced hypothermic response and protects mice from superantigeninduced toxic shock. Antimicrob Agents Chemother 2006; 50:391-5; PMID:16377721; http://dx.doi.org/10.1128/AAC.50.1.391-395.2006
131. Rieder SA, Nagarkatti P, Nagarkatti M. Multiple antiinflammatory pathways triggered by resveratrol lead to amelioration of staphylococcal enterotoxin B-induced lung injury. Br J Pharmacol 2012; 167:1244-58; PMID:22646800; http://dx.doi.org/10.1111/j.1476-5381.2012.02063.x
132. Choi K, Lee K, Ryu SW, Im M, Kook KH, Choi C. Pirfenidone inhibits transforming growth factor β1-induced fibrogenesis by blocking nuclear translocation of Smads in human retinal pigment epithelial cell line ARPE-19. Mol Vis 2012; 18:1010-20; PMID:22550395.
133. Takei Y, Kunikata T, Aga M, Inoue S, Ushio S, Iwaki K, et al. Tryptanthrin inhibits interferon-γ production by Peyer's patch lymphocytes derived from mice that had been orally administered staphylococcal enterotoxin. Biol Pharm Bull 2003; 26:365-7; PMID:12612449; http://dx.doi.org/10.1248/bpb.26.365
134. Pergola C, Jazzar B, Rossi A, Northoff H, Hamburger M, Sautebin L, et al. On the inhibition of 5-lipoxygenase product formation by tryptanthrin: mechanistic studies and efficacy in vivo. Br J Pharmacol 2012; 165:765-76; PMID:21797843; http://dx.doi.org/10.1111/j.1476-5381.2011.01605.x
135. Chen X, Krakauer T, Oppenheim JJ, Howard OM. Yin zi huang, an injectable multicomponent chinese herbal medicine, is a potent inhibitor of T-cell activation. J Altern Complement Med 2004; 10:519-26; PMID:15253857; http://dx.doi.org/10.1089/1075553041323687
136. Watson JL, Vicario M, Wang A, Moreto M, McKay DM. Immune cell activation and subsequent epithelial dysfunction by Staphylococcus enterotoxin B is attenuated by the green tea polyphenol (-)-epigallocatechin gallate. Cell Immunol 2005; 237:7-16; PMID:16213476; http://dx.doi.org/10.1016/j.cellimm.2005.08.030
137. Krakauer T, Li BQ, Young H. The flavonoid baicalin inhibits staphylococcal superantigen-induced inflammatory cytokines and chemokines. FEBS Lett 2001; 500:52-5; PMID:11434925; http://dx.doi.org/10.1016/S0014-5793(01)02584-4
138. Saha B, Jaklic B, Harlan DM, Gray GS, June CH, Abe R. Toxic shock syndrome toxin-1-induced death is prevented by CTLA4Ig. J Immunol 1996; 157:3869-75; PMID:8892617.
139. Krakauer T, Buckley M, Issaq HJ, Fox SD. Rapamycin protects mice from staphylococcal enterotoxin B-induced toxic shock and blocks cytokine release in vitro and in vivo. Antimicrob Agents Chemother 2010; 54:1125-31; PMID:20086156; http://dx.doi.org/10.1128/AAC.01015-09
140. Thomson AW, Turnquist HR, Raimondi G. Immunoregulatory functions of mTOR inhibition. Nat Rev Immunol 2009; 9:324-37; PMID:19390566; http://dx.doi.org/10.1038/nri2546
141. Kissner TL, Moisan L, Mann E, Alam S, Ruthel G, Ulrich RG, et al. A small molecule that mimics the BB-loop in the Toll interleukin-1 (IL-1) receptor domain of MyD88 attenuates staphylococcal enterotoxin B-induced pro-inflammatory cytokine production and toxicity in mice. J Biol Chem 2011; 286:31385-96; PMID:21693701; http://dx.doi.org/10.1074/jbc.M110.204982
142. Jo D, Liu D, Yao S, Collins RD, Hawiger J. Intracellular protein therapy with SOCS3 inhibits inflammation and apoptosis. Nat Med 2005; 11:892-8; PMID:16007096; http://dx.doi.org/10.1038/nm1269
143. Sun J, Law GP, Bridges CC, McKallip RJ. CD44 as a novel target for treatment of staphylococcal enterotoxin B-induced acute inflammatory lung injury. Clin Immunol 2012; 144:41-52; PMID:22659034; http://dx.doi.org/10.1016/j.clim.2012.05.001
144. Kansal R, Davis C, Hansmann M, Seymour J, Parsonnet J, Modern P, et al. Structural and functional properties of antibodies to the superantigen TSST-1 and their relationship to menstrual toxic shock syndrome. J Clin Immunol 2007; 27:327-38; PMID:17340193; http://dx.doi.org/10.1007/s10875-007-9072-4
145. Adhikari RP, Ajao AO, Aman MJ, Karauzum H, Sarwar J, Lydecker AD, et al. Lower antibody levels to Staphylococcus aureus exotoxins are associated with sepsis in hospitalized adults with invasive S. aureus infections. J Infect Dis 2012; 206:915-23; PMID:22807524; http://dx.doi.org/10.1093/infdis/jis462
146. Darenberg J, Söderquist B, Normark BH, NorrbyTeglund A. Differences in potency of intravenous polyspecific immunoglobulin G against streptococcal and staphylococcal superantigens: implications for therapy of toxic shock syndrome. Clin Infect Dis 2004; 38:836-42; PMID:14999628; http://dx.doi.org/10.1086/381979
147. Ohlsen K, Lorenz U. Immunotherapeutic strategies to combat staphylococcal infections. Int J Med Microbiol 2010; 300:402-10; PMID:20547101; http://dx.doi.org/10.1016/j.ijmm.2010.04.015
148. Karauzum H, Chen G, Abaandou L, Mahmoudieh M, Boroun AR, Shulenin S, et al. Synthetic human monoclonal antibodies toward staphylococcal enterotoxin B (SEB) protective against toxic shock syndrome. J Biol Chem 2012; 287:25203-15; PMID:22645125; http://dx.doi.org/10.1074/jbc.M112.364075
149. Graef RR, Anderson GP, Doyle KA, Zabetakis D, Sutton FN, Liu JL, et al. Isolation of a highly thermal stable lama single domain antibody specific for Staphylococcus aureus enterotoxin B. BMC Biotechnol 2011; 11:86; PMID:21933444; http://dx.doi.org/10.1186/1472-6750-11-86
150. Urushibata Y, Itoh K, Ohshima M, Seto Y. Generation of Fab fragment-like molecular recognition proteins against staphylococcal enterotoxin B by phage display technology. Clin Vaccine Immunol 2010; 17:1708-17; PMID:20844088; http://dx.doi.org/10.1128/CVI.00229-10
151. Kohler PL, Greenwood SD, Nookala S, Kotb M, Kranz DM, Schlievert PM. Staphylococcus aureus isolates encode variant staphylococcal enterotoxin B proteins that are diverse in superantigenicity and lethality. PLoS One 2012; 7:e41157; PMID:22815951; http://dx.doi.org/10.1371/journal.pone.0041157
152. LeClaire RD, Hunt RE, Bavari S. Protection against bacterial superantigen staphylococcal enterotoxin B by passive vaccination. Infect Immun 2002; 70:2278-81; PMID:11953360; http://dx.doi.org/10.1128/IAI.70.5.2278-2281.2002
153. Woody MA, Krakauer T, Ulrich RG, Stiles BG. Differential immune responses to staphylococcal enterotoxin B mutations in a hydrophobic loop dominating the interface with major histocompatibility complex class II receptors. J Infect Dis 1998; 177:1013-22; PMID:9534976; http://dx.doi.org/10.1086/515250
154. Inskeep TK, Stahl C, Odle J, Oakes J, Hudson L, Bost KL, et al. Oral vaccine formulations stimulate mucosal and systemic antibody responses against staphylococcal enterotoxin B in a piglet model. Clin Vaccine Immunol 2010; 17:1163-9; PMID:20554806; http://dx.doi.org/10.1128/CVI.00078-10
155. Madej T, Addess KJ, Fong JH, Geer LY, Geer RC, Lanczycki CJ, et al. MMDB: 3D structures and macromolecular interactions. Nucleic Acids Res 2012; 40(Database issue):D461-4; PMID:22135289; http://dx.doi.org/10.1093/nar/gkr1162